Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 7, 2004

View Archived Issues

Isovaleramide advances into phase IIa study in migraine

Phase Ib study evaluates aerosolized surfactant therapy for asthma

Axonyx expands scope of phenserine phase IIb clinical trial

Confirmatory data supports phase II Resten-NG data

Five years exclusive Indian marketing rights for Nadoxin

Uni-Gold Recombigen HIV test receives FDA approval

Symbyax approved for bipolar depressive episodes

NDA submission for once-daily Allegra-D

ISIS-301012 enters phase I study for treatment of cardiovascular disease

Pharmion submits Vidaza NDA

Neurodex evaluated for pseudobulbar affect

Aventis scientists prepare and test new cathepsin K inhibitors

Kirin Brewery presents new inhibitors of Bcl-2/Bcl-xL with utility in cancer therapy

Novel libraries of antibacterial compounds prepared at Lion Bioscience

Mitsui Chemicals patent covers new agents for telomerase-mediated disorders

New antitumor azoles in early development at Sankyo

Coremed plans clinical trials for Alveair insulin technology

Alvesco NDA submission for persistent asthma

Shipments of TriNessa commence

DX-88 meets primary endpoints in phase I/II study

Japanese trials of HGF genetic medicine cleared to begin

Nascobal Nasal Spray submitted for FDA approval

AVI-4020 safe in phase I/II West Nile trial

Kyorin discontinues development of KRP-297

NDA filing for Arcoxia

Ivabradine has no adverse effects on the LVEF of patients with left ventricular dysfunction

Prolonged inhibition of spermatogenesis found with subcutaneous MENT implants

A novel triple therapy improves glucose metabolism in obese patients with type 2 diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...